Syngene International Analysis

dividend

Pros

Cons

• Unable to calculate sustainability of dividends as Syngene International has not reported any payouts.
• Unable to evaluate Syngene International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
• Unable to evaluate Syngene International's dividend against the top 25% market benchmark as the company has not reported any payouts.

future

Pros

• Performance (ROE) is expected to be above the current IN Life Sciences industry average.
• Syngene International's revenue growth is expected to exceed the India market average.

Cons

• Syngene International's earnings are expected to grow by 1.5% yearly, however this is not considered high growth (20% yearly).
• Syngene International's earnings growth is positive but not above the India market average.
• Syngene International's earnings growth is positive but not above the low risk savings rate of 7.2%.
• Syngene International's earnings are expected to decrease over the next year.
• Syngene International's net income is expected to increase but not above the 50% threshold in 2 years time.
• Syngene International is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
• A decline in Syngene International's performance (ROE) is expected over the next 3 years.
• Syngene International's revenue is expected to increase but not above the 50% threshold in 2 years time.
• Syngene International's revenue is expected to grow by 9.5% yearly, however this is not considered high growth (20% yearly).

health

Pros

• Syngene International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
• Syngene International is profitable, therefore cash runway is not a concern.
• Syngene International is profitable, therefore cash runway is not a concern.
• Debt is well covered by operating cash flow (84.2%, greater than 20% of total debt).
• Debt is covered by short term assets, assets are 2x debt.
• Syngene International's cash and other short term assets cover its long term commitments.
• Interest payments on debt are well covered by earnings (EBIT is 11.1x coverage).
• Syngene International's level of debt (36.9%) compared to net worth is satisfactory (less than 40%).

Cons

• The level of debt compared to net worth has increased over the past 5 years (19.4% vs 36.9% today).
• High level of physical assets or inventory.

management

Pros

• The tenure for the Syngene International board of directors is about average.
• Jonathan's compensation has been consistent with company performance over the past year, both up more than 20%.

Cons

• Jonathan's remuneration is higher than average for companies of similar size in India.
• Syngene International individual insiders have only sold shares in the past 3 months.
• The average tenure for the Syngene International management team is less than 2 years, this suggests a new team.

misc

Pros

Cons

• Syngene International is covered by less than 3 analysts.
• Syngene International has significant price volatility in the past 3 months.

past

Pros

• Syngene International's 1-year earnings growth exceeds its 5-year average (24.3% vs 14.4%)
• Syngene International's year on year earnings growth rate has been positive over the past 5 years.
• Syngene International used its assets more efficiently than the IN Life Sciences industry average last year based on Return on Assets.
• Syngene International has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
• Syngene International's earnings growth has exceeded the IN Life Sciences industry average in the past year (24.3% vs -6.2%).

Cons

• Syngene International has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).

value

Pros

• 539268 outperformed the Market in India which returned -14.5% over the past year.
• BSE:539268 is up 9% outperforming the Life Sciences industry which returned 2.6% over the past month.
• BSE:539268 is up 9% outperforming the market in India which returned 8% over the past month.

Cons

• Syngene International's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
• Syngene International's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
• Syngene International is overvalued based on assets compared to the IN Life Sciences industry average.
• Syngene International is poor value based on expected growth next year.
• Syngene International is overvalued based on earnings compared to the IN Life Sciences industry average.
• Syngene International is overvalued based on earnings compared to the India market.
• 539268 underperformed the Life Sciences industry which returned 36.1% over the past year.